Despite the relatively low positivity of IRF4 in BCL2 overexpressed cases (from 18% to 44%),46, 47 as BCL2 overexpression is not only found in DLBCL harbouring IGH::BCL2 translocation but also resulted from BCL2 gene amplification or ORF mutation,31 IRF4‐targeted therapy may be beneficial in these DLBCL subsets. Here, IRF4 is linked to diffuse large B-cell lymphoma.